Kornimate/medical-research-clean huggingface dataset:
investigating muscle repair in response to icing therapy post eccentric muscle damage exercise

Conditions: Muscle Damage

Summary: the purpose of our research is to investigate the effects of applying cold therapy, or "icing," to injured muscles in terms of strength recovery and muscle soreness amelioration following unaccustomed exercise.

the objective is to determine whether or not injured muscles that are subject to icing after eccentrically damaging exercise recover their strength quicker and/or have less muscle soreness than those that do not receive any icing treatment after damaging exercise and if any differences in effectiveness between two icing protocols exist. baseline measures of peak torque of the dominant arm's elbow flexor muscles will be measured by concentric and isometric contractions prior to participants undergoing eccentric muscle damaging exercise. participants will be randomly assigned into 3 different experimental groups of approximately 15 participants each. the first group will begin "icing protocol 1" at time 0 (or as close to). the second group will begin "icing protocol 2" six hours after their initial eccentric muscle damaging exercise. the remaining group will not receive any icing treatment; they are the control group. participants will be brought back into the lab at specific post-exercise times (0h, 24h, 48h, 96h, and 7 days) to complete peak torque measures as they did with baseline measures prior to eccentric muscle damage. measures of delayed onset muscle soreness (doms) will also be taken at baseline and during scheduled follow up times for participants.

Eligibility criteria:
inclusion criteria: * healthy students attending wilfrid laurier university with no previous history of upper body muscle damage and live in close proximity to the university so they can attend all lab sessions. ideally they have not performed any upper body resistance training within the last 4 months. exclusion criteria: * previous history of muscle, joint, or ligament injuries in the surrounding area of their dominant are elbow flexor region.

Keywords: muscle muscle repair tissue repair eccentric exercise force loss icing cold therapy doms soreness recovery
proximal femur locking compression plates versus trochanteric nails

Conditions: Reverse Oblique Intertrochanteric Fractures; Reverse Oblique Subtrochanteric Fractures

Summary: the purpose of this study is to compare the abductor muscle strength measured with a dynamometer in patients with reverse oblique inter- or subtrochanteric fractures treated either with a proximal femur locking plate or a trochanteric nail. "proximal femur locking plates" stands for both the pf-lcp (synthes) and the periloc (smith \& nephew). trochanteric nails allowed in this study are the proximal femoral nail antirotation (pfna), the titanium trochanteric fixation nail (tfn) and the gamma nail (gn).


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * patients with closed or type 1 open reverse oblique intertrochanteric fractures (ao 31 - a3) or subtrochanteric fractures (transverse fracture line, main fracture line maximum 5 cm distal from the lesser trochanter; proximal extension of fracture allowed) * definitive fracture fixation with either a proximal femur locking plate or an intertrochanteric nail within 4 days after accident * signed written informed consent (by the subject or legal guardian) and agreement to attend the planned fus * able to understand and read country national language at an elementary level exclusion criteria: * pathologic fracture * polytrauma * any displacement of a femoral neck fracture * additional fracture of one of the lower extremities that significantly affects the functional outcome * additional injury of the lower limb that significantly affects the functional outcome * fractures of the upper extremity if it affects the mobility of the patient * type 2 or 3 open fracture * drug or alcohol abuse * active malignancy * asa class v and vi * inability to walk independently prior to injury * neurological and psychiatric disorders that would preclude reliable assessment * patient is not able to come to the regular fus * patients who have participated in any other device or drug related clinical trial within the previous month * pregnancy (tested with a urine pregnancy test) or women planning to conceive within the study period

Keywords: reverse oblique intertrochanteric fractures reverse oblique subtrochanteric fractures
simulated walking with multiplexing prism for field expansion in monocular vision

Conditions: One Eye Blindness; Blind Left Eye; Blind Right Eye

Summary: the investigators are developing an assistive device, known as multiplexing prism that expands the field of view for individuals with acquired monocular vision (loss of an eye). the investigators will test the efficacy of the prism in improving the detection of colliding pedestrians during a simulated walking task.


Eligibility criteria:
inclusion criteria: * no medical health issues such as seizures, motor movements problem * loss of vision in one eye (less than 20/200) for \>1 year * visual acuity of the seeing eye: better than 20/32 visual acuity with correction * no visual field defect in the seeing eye (nasal field of at least \>45degree) exclusion criteria: * patients with any physical or mental disabilities, including cognitive dysfunction, balance problems, or other deficits that could impair their ability to respond to the stimuli presented in this study will be excluded * any person with a history (such as pacemaker use or photosensitive epilepsy) * any person with motor movements problem (e.g., unable to use extremities)

Keywords: simulated walking collision field expansion one eye blindness
systems aligning for equity (safe) spaces

Conditions: Suicide; Mental Disorder; Mental Health; Burnout, Professional; Self Harm

Summary: the goal of this 2-arm cluster randomized clinical trial is to test whether an evidence-based staff training and coaching model specifically designed as a response to legal system-involved youths' and frontline staff's mental health needs can improve the safety and suicide outcomes, mental health challenges, and wellness and facility climate for youth and staff in facilities assigned to the intervention condition. staff in facilities assigned to the intervention are eligible to receive evidence-based programming in suicide detection and prevention (shield of care; soc) and wellness skill-building (skills for life) through training and personalized coaching. multiple training sessions will be offered to small groups of staff in-person in residential facilities and paired with personalized in-person and virtual coaching. staff and youth in all facilities will be asked to complete periodic surveys assessing experiences in the facility, suicide and safety knowledge and risk, and their mental health and wellness. researchers will compare outcomes of staff in youth in facilities assigned to the intervention compared to facilities in the training-as-usual condition.


Eligibility criteria:
inclusion criteria: * placement in in acs-run or contracted residential facilities enrolled in the study during the first 2 years of the intervention period * proficiency in english exclusion criteria: * not placed in an acs run-or contracted facility enrolled in the study during the study period * lack of proficiency in english.
global collaboration on cic-dux4, bcor-ccn3, high-grade undifferentiated round cell sarcoma (urcs) project

Conditions: Undifferentiated Round Cell Sarcoma

Summary: experimental study with biological material : case series review of clinical and histological data

this is a multicenter retrospective and prospective study that will analyze all cases with a diagnosis of undifferentiated round cell sarcomas from 01 january 1983 and all new cases referring to each participant site.

Eligibility criteria:
inclusion criteria: * patients with undifferentiated round cell sarcomas treated from 01 january 1983 and all new patients will be included. * clinical and outcome information available. * histological slides/formalin-fixed paraffin-embedded tissue tumor blocks from archive available to perform the histology analysis/frozen tissue representative of the tumor available. exclusion criteria: * diagnosis different from undifferentiated round cell sarcomas * patient with no clinical or outcome information available
air tamponade in macular hole surgery

Conditions: Macular Hole

Summary: macular hole is a hole formation which takes place in the center of the retina. such a hole needs surgical steps in order to close. closure of the macular hole will lead to a substantially improvement of vision in most cases. following macular hole surgery a tamponade of intraocular gas is normally injected in order to keep the macula dry for the postoperative period. postoperative face down position for a week was earlier standard. several authors report of good closure rates with both air tamponade or lack of face down positioning. in this study standard pars plana vitrectomy with peeling of the internal limiting membrane (ilm) will be performed. the gas tamponade will be replaced by air. postoperative face down positioning will not be used.


Eligibility criteria:
inclusion criteria: * idiopathic stage 2 - 4 macular hole * duration of symptoms ≤ 36 months * informed consent exclusion criteria: * previous vitreomacular surgery * myopia ≥ 6 diopters * ocular trauma * disease affecting visual function

Keywords: macular hole vitreoretinal surgery macular surgery air tamponade
use of hypotension prediction index to reduce intraoperative hypotension in major thoracic surgery

Conditions: Hypotension During Surgery

Summary: intraoperative hypotension is linked to increased incidence of perioperative adverse events such as myocardial and cerebrovascular infarction and acute kidney injury. hypotension prediction index (hpi) is a novel machine learning guided algorithm which can predict hypotensive events using high fidelity analysis of pulse-wave contour. goal of this trial is to determine whether use of hpi can reduce the number and duration of hypotensive events in patients undergoing major thoracic procedures.


Eligibility criteria:
inclusion criteria: * patients over 18 years of age * patients scheduled for elective major thoracic procedure (lung resection, pleurectomy or resection of the esophagus) * planned thoracotomy and intraoperative period of one lung ventilation * planned postoperative admission to the icu exclusion criteria: * persistent atrial fibrillation * structural heart defects (shunting or moderate to severe valvular anomalies) * preoperative serum hemoglobin levels \< 120 g/l * severe heart failure classified as new york heart association (nyha) grade iv
a clinical study to evaluate the efficacy and safety of subcutaneous js005 injection in the treatment of adults with moderate to severe chronic plaque psoriasis

Conditions: Moderate to Severe Chronic Plaque Psoriasis

Summary: this is a multicenter, randomized, double-blind, parallel, placebo-controlled phase iii clinical study to evaluate the efficacy and safety of js005 in 702 adult patients with moderate-to-severe chronic plaque psoriasis

the study consisted of four periods: screening period (up to 4 weeks), induction period (12 weeks), maintenance period (40 weeks) and follow-up period (8 weeks). this study planned to recruit 702 subjects, who were randomized into js005 300mg group (234 subjects), js005 150mg group (234 subjects) and placebo group (234 subjects) at a ratio of 1:1:1, and were stratified by whether they had previsouly received biologic treatments (continuous biologic treatment for ≥3 months at recommended doses or intolerance for safety reasons) and body weight (≥70 kg or \< 70 kg).

Eligibility criteria:
inclusion criteria: 1. subjects voluntarily particpate in this clinical study and sign the informed consent form. 2. male and female patients aged 18-75 years at the time of screening (both inclusive). 3. fertile female subjects must be willing to use a highly effective contraceptive method during the study period and 20 weeks (expected 5 half-lives) after the last study drug administration and have a negative pregnancy test during the screening period and prior to randomization. exclusion criteria: 1. pregnant and lactating women. 2. a history of inflammatory bowel disease or other conditions with a high risk of perforation (e.g., severe gastrointestinal ulcers, etc.) or with other active autoimmune diseases (e.g., systemic lupus erythematosus, sarcoidosis, etc.). 3. have a type of psoriasis other than chronic plaque psoriasis (e.g., pustular, erythrodermic, and guttate psoriasis), drug-induced psoriasis, or have an active inflammatory skin disease other than psoriasis 4. use of phototherapy, including but not limited to ultraviolet a phototherapy (with or without psoralens), ultraviolet b phototherapy, or excimer laser within 4 weeks prior to randomization. subjects are unwilling to avoid excessive sunlight exposure within 4 weeks prior to randomization and during the study period; 5. a (current) history of systemic infection or serious infection requiring hospitalization and/or intravenous anti-infective therapy (e.g., antibiotics, antifungal agents, antiviral agents) within 12 weeks prior to randomization; a history of any active infection, other than common upper respiratory infections, within 2 weeks prior to randomization;
phase iii clinical study of pegylated somatropin (peg somatropin) to treat growth hormone deficiency children

Conditions: Growth Hormone Deficiency

Summary: this was a multicenter, randomized, open-label, parallel controlled phase iii study, compared pegylated somatropin with jintropin aq (somatropin liquid injection, daily administration formulation). all the subjects were randomized into two groups, test group (peg somatorpin) and control group (jintropin aq), 200 children were enrolled in test group and 100 children were enrolled in control group. considering the case loss during the clinical study, 20% of the patients were added in each of the group, that is 240 children were in test group and 120 children were in control group, totally 360 children were enrolled in the phase iii clinical study. whole treatment were lasted for 6 months, 4 times of follow-up were carried out at the point of baseline, 1 month, 3 month and 6 month after treatment. the evaluation of the primary time point was 3 month and 6 month after treatment, if the treatment was less than 6 months, the evaluation would be made when the treatment is finished.


Eligibility criteria:
inclusion criteria: * 1. subjects have a height less than two standard deviations (sd) below the median height for individuals of he same age or height,the growth velocity (cv≤4.0 cm/yr),gh peak concentration \<7.0ng/ml in two difference provocative tests, bone age (ba) ≤9 years in girls and ≤10 years in boys, at least 2 year less than his/her chronological age (ca) * be in preadolescence (tanner stage 1) and have a ca \> 3 years * have a height value recorded 3 months before the start of gh treatment to calculate pre-treatment gv. * receive no prior gh treatment. * sign informed consent exclusion criteria: * 1. patients positive for hepatitis b e-antibody (hbeab), hepatitis b surface antigen (hbsag) or hepatitis b e antigen (hbeag) * 2.known hypersensitivity to somatropin or any other components of the study product. * 3. severe cardiopulmonary or hematological diseases, a current or past history of malignant tumors, immunodeficiency diseases, or mental diseases * 4. with other growth disorders, such as turner syndrome, constitutional delay of growth and puberty, and laron syndrome * 5. subjects took part in other clinical trial study during 3 months. * 6. other conditions which in the opinion of the investigator preclude enrollment into the study.

Keywords: pegylated somatropin peg-rhgh growth hormone growth hormone deficiency phase iii study
eligible (efficacy of left atrial appendage closure after gastrointestinal bleeding)

Conditions: Adverse Reaction to Drugs Affecting the Gastrointestinal System

Summary: patients with atrial fibrillation requiring anticoagulation treatment are at high risk of gastrointestinal bleeding. the investigators propose the percutaneous stop the oral anticoagulation and closure of the left atrial appendage with the amplatzer ® system in patients receiving anticoagulant therapy for atrial fibrillation without associated valvular heart disease, to reduce significantly the risk of stroke while minimizing the risk of bleeding in a group of patients with high risk for both events. eligible trial(left atrial appendage efficacy of gastrointestinal bleeding after closure) is a prospective, multicentric and randomized (2 to 1) trial, comparing percutaneous closure of atrial appendage left versus standard treatment with oral anticoagulants in patients with history of gastrointestinal bleeding and high embolic risk.


Eligibility criteria:
inclusion criteria: * documented atrial fibrilation (paroxysmal or permanent) without significant heart valve disease * \> 18 years * classic oral anticoagulation(inr at therapeutic levels: 2-3) or new oral anticoagulants * cha2-ds2-vasc score ≥ 3 * prior digestive bleeding without any treatable cause * informed consent. exclusion criteria: * pof * contraindication to further treatment with dual antiplatelet therapy (aspirin + clopidogrel) * intracardiac thrombus * significant carotid disease * cardioversion scheduled within 30 days following the implantation * af not controlled by fvm\> 100 bpm * af secondary to surgery or ablation * thrombosis in patients \<40 years * chronic renal insufficiency with cr clearance \<30 ml 2 * left appendage sizeappendage with inlet \ 28.5 (ete) * depth of the appendage \<10mm in the tee

Keywords: left atrial appendage occlusion gastrointestinal bleeding
supramaximal rectus recession for strabismus in grave's ophthalmopathy

Conditions: Strabismus, Mechanical; Graves Ophthalmopathy

Summary: the purpose of this study is to evaluate supramaximal rectus recession for strabismus in grave's ophthalmopathy

to evaluate the effectiveness and complications of supramaximal rectus recession for large-angle strabismus in grave's ophthalmopathy

Eligibility criteria:
inclusion criteria: * clinical diagnosis of grave's ophthalmopathy * angle of deviation more than 20° * clinically and biochemically euthyroid for at least 3 months; * a stable orthoptic examination for at least 3 months, for example no greater than five prism dioptre change in primary position and no greater than an 8° change in duction * monocular and mainly single extraocular muscle restricted motility exclusion criteria: * patients with suppression, previously diagnosed and/or treated strabismus not related to the thyroid * best-corrected visual acuity (bcva) less than 0.2 in one or both eyes
evaluation of patient education in irritable bowel syndrome

Conditions: Irritable Bowel Syndrome

Summary: about 10% of the population in western countries suffer from abdominal pain and change of bowel habits - known as the irritable bowel syndrome. the patients suffer from low quality of life and they are often not well taken care of within the public healthcare system. they often feel frustrated and seek both their family doctors, specialists and alternative medicine for help. many patients feel they do not know enough about their disease, and the uncertainty may enhance bowel symptoms. we want to evaluate the effect of patient information and education in these patients.

the patients are enrolled in endoscopic clinics in 7 hospitals in norway. they are randomized to receive intervention now (intervention group) or in 6 months (control group). the intervention is a 6 hour education about the irritable bowel syndrome, held by a experienced gastroenterologist at the local hospital. elements in this "school-day" includes symptoms, epidemiology, pathophysiology, treatment, nutritional advices. the patients are evaluated at time: 0 months and 6 months (intervention group and control group), 12 months (control group) and after 2 years (both groups).

Eligibility criteria:
inclusion criteria: * a diagnosis of irritable bowel syndrome, verified by the rome ii criteria * must be able to participate in a education-group exclusion criteria: * another gi-diagnosis or kind of surgery that may interfere with the symptoms of irritable bowel syndrome * serious, untreated psychiatric disorder

Keywords: quality of life gastrointestinal symptoms health related costs
evaluation of symptoms improvement in nsclc patients with first-line therapy of egfr tyrosine kinase inhibitor

Conditions: Non-Small-Cell Lung Cancer

Summary: this is an open-label, non-interventional, single-arm, multicenter study in a real-world population to assess the clinically symptom improvement and quality of life (qol) in patients with locally advanced or metastatic nsclc and positive egfr mutation who receive egfr-tkis as the first-line treatment. the primary objective is to estimate symptom improvement rates in patients with locally advanced or metastatic nsclc and positive egfr mutation who receive egfr-tkis as the first-line treatment. a clinically meaningful improvement is defined as an increase from baseline of 2 or more points for lcs (lung cancer scales) at week 4.

the secondary objectives are: 1. to estimate symptom improvement rates at weeks 2 and 12 2. to estimate mean change from baseline in overall qol scores using the fact-l instrument and lcs score at week 2, 4 and 12. 3. to estimate the proportion of patients exhibiting an lcs change of 7 points or more at weeks 2, 4 and 12. 4. subgroup information of symptom improvement rate, qol and disease-related symptom scores by gender, smoking status, smoking pattern, who performance, number of metastatic sites, female/never smokers and patients with copd at week 2, week 4 and week 12.

Eligibility criteria:
inclusion criteria: * patients diagnosed with symptomatic, locally advanced or metastatic (stage iiib/iv) nsclc. * patients who are positive for egfr mutation * patients with a prescription of egfr-tki as their first-line treatment exclusion criteria: - involvement in any planning and/or conduct of the clinical trial.